297 related articles for article (PubMed ID: 16213066)
1. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.
de Bruyn G; Vargas-Cortez M; Warren T; Tyring SK; Fife KH; Lalezari J; Brady RC; Shahmanesh M; Kinghorn G; Beutner KR; Patel R; Drehobl MA; Horner P; Kurtz TO; McDermott S; Wald A; Corey L
Vaccine; 2006 Feb; 24(7):914-20. PubMed ID: 16213066
[TBL] [Abstract][Full Text] [Related]
2. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
3. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
Wald A; Zeh J; Selke S; Warren T; Ryncarz AJ; Ashley R; Krieger JN; Corey L
N Engl J Med; 2000 Mar; 342(12):844-50. PubMed ID: 10727588
[TBL] [Abstract][Full Text] [Related]
5. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
6. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
7. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
Leone P
Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
[TBL] [Abstract][Full Text] [Related]
8. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.
Mark KE; Corey L; Meng TC; Magaret AS; Huang ML; Selke S; Slade HB; Tyring SK; Warren T; Sacks SL; Leone P; Bergland VA; Wald A
J Infect Dis; 2007 May; 195(9):1324-31. PubMed ID: 17397003
[TBL] [Abstract][Full Text] [Related]
9. Virologic characteristics of subclinical and symptomatic genital herpes infections.
Wald A; Zeh J; Selke S; Ashley RL; Corey L
N Engl J Med; 1995 Sep; 333(12):770-5. PubMed ID: 7643884
[TBL] [Abstract][Full Text] [Related]
10. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.
Wald A; Carrell D; Remington M; Kexel E; Zeh J; Corey L
Clin Infect Dis; 2002 Apr; 34(7):944-8. PubMed ID: 11880960
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
[TBL] [Abstract][Full Text] [Related]
12. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
[TBL] [Abstract][Full Text] [Related]
14. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.
Kim HN; Meier A; Huang ML; Kuntz S; Selke S; Celum C; Corey L; Wald A
J Infect Dis; 2006 Aug; 194(4):420-7. PubMed ID: 16845624
[TBL] [Abstract][Full Text] [Related]
15. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for herpes simplex virus infections.
Koelle DM
Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
[TBL] [Abstract][Full Text] [Related]
17. [Herpes simplex virus vaccine studies: from past to present].
Us D
Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
[TBL] [Abstract][Full Text] [Related]
18. Isolation of herpes simplex virus from the genital tract during symptomatic recurrence on the buttocks.
Kerkering K; Gardella C; Selke S; Krantz E; Corey L; Wald A
Obstet Gynecol; 2006 Oct; 108(4):947-52. PubMed ID: 17012458
[TBL] [Abstract][Full Text] [Related]
19. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
20. The Holy Grail: immune control of human herpes simplex virus infection and disease.
Cunningham AL; Mikloska Z
Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
